Novel Liposomal Active Immunotherapy Targeting pTau in Alzheimer’s Disease
Time: 4:00 pm
day: Conference Day Two PM
Details:
- Introducing potentially pivotal phase 2b study testing JNJ-64042056 in A+T+ preclinical AD
- Early learnings and insights from precision medicine approach to pre-screening directly from diverse communities with pT217
- Utilizing MOA-based precision neuroimaging measures to quantify spread of tau pathology
